Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | PTGER4 | P35408 | 7/20 | 0.44 |
| ▸ | PTGER3 | P43115 | 7/20 | 0.44 |
| ▸ | PTGER1 | P34995 | 7/20 | 0.44 |
| ▸ | PTGER2 | P43116 | 6/20 | 0.44 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | GAPDH | P04406 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4280202 | 0.86 | GAPDH (0.44) | MAOBCYP3A4BACE1GAPDHCD274 | |
| SCHEMBL4279254 | 0.83 | GAPDH (0.41) | MAOBCYP3A4BACE1GAPDHCD274 | |
| SCHEMBL4279998 | 0.82 | GAPDH (0.41) | MAOBCYP3A4BACE1GAPDH | |
| SCHEMBL4281602 | 0.81 | PDE4D (0.43) | MAOBCYP3A4FFAR1BACE1GAPDH | |
| SCHEMBL4280169 | 0.80 | PTGER1 (0.43) | PTGER4PTGER3PTGER1PTGER2 | |
| SCHEMBL4283005 | 0.79 | GAPDH (0.44) | MAOBCYP3A4BACE1GAPDH | |
| SCHEMBL7466776 | 0.78 | GSTP1 (0.42) | MAOBPTGER4PTGER3PTGER1PTGER2 | |
| SCHEMBL7461083 | 0.77 | MAOB (0.51) | MAOBMRGPRX4 | |
| SCHEMBL4278542 | 0.76 | LMNA (0.51) | MAOBCYP3A4BACE1GAPDH | |
| SCHEMBL5746820 | 0.76 | MAOB (0.68) | MAOBMRGPRX4CYP3A4FFAR1NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2397462-A2 | Compounds, compositions and methods of treatment for heart failure | Cytokinetics, Inc. (US) | 2011-12-21 | — | — | EP | disclosed |
| US-20090176307-A1 | Compounds, Compositions and Methods | CYTOKINETICS, INC. | 2009-07-09 | — | — | US | disclosed |
| US-7491826-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-7399866-B2 | Compounds, compositions, and methods | CYTOKINETICS, INC. (US) | 2008-07-15 | — | — | US | disclosed |
| US-20060241110-A1 | Compounds, compositions, and methods | CYTOKINETICS, INCORPORATED | 2006-10-26 | — | — | US | disclosed |
| US-20050159416-A1 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED | 2005-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241110-A1 | Compounds, compositions, and methods | TNNI3, TNNT2, TNNC1 | MAOB 2129/4885PTGER4 3707/4885PTGER3 3255/4885 |
| US-20050159416-A1 | Compounds, compositions and methods | TNNI3, TNNC1, TNNT2 | MAOB 2315/4885PTGER4 3696/4885PTGER3 3218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.